Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Overview | 8 | 1 |
| Therapeutics Development | 9 | 4 |
| Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Products under Development by Stage of Development | 9 | 1 |
| Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Products under Development by Therapy Area | 10 | 1 |
| Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Products under Development by Indication | 11 | 2 |
| Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Products under Development by Companies | 15 | 3 |
| Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Products under Development by Universities/Institutes | 18 | 2 |
| Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Therapeutics Assessment | 20 | 7 |
| Assessment by Monotherapy/Combination Products | 20 | 1 |
| Assessment by Mechanism of Action | 21 | 2 |
| Assessment by Route of Administration | 23 | 2 |
| Assessment by Molecule Type | 25 | 2 |
| Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Companies Involved in Therapeutics Development | 27 | 10 |
| Aptevo Therapeutics Inc | 27 | 1 |
| ARMO Biosciences, Inc. | 28 | 1 |
| BioMAS Ltd. | 29 | 1 |
| Biotest AG | 30 | 1 |
| enGene, Inc | 31 | 1 |
| Intrexon Corporation | 32 | 1 |
| LEO Pharma A/S | 33 | 1 |
| Merck &Co., Inc. | 34 | 1 |
| P2D Bioscience | 35 | 1 |
| Pfizer Inc. | 36 | 1 |
| Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Drug Profiles | 37 | 24 |
| AM-0010 Drug Profile | 37 | 3 |
| ANV-103 Drug Profile | 40 | 1 |
| Biologic to Activate Glutamic Acid Decarboxylase and IL-10 for Type 1 Diabetes Drug Profile | 41 | 1 |
| Biologic to Target Insulin Receptor and IL-10 for Type 1 Diabetes Drug Profile | 42 | 1 |
| BT-063 Drug Profile | 43 | 1 |
| CB-0602 Drug Profile | 44 | 2 |
| CTLA-4 X mono-IL-10 Drug Profile | 46 | 1 |
| Dekavil Drug Profile | 47 | 2 |
| EG-10 Drug Profile | 49 | 1 |
| EG-12 Drug Profile | 50 | 1 |
| Elmyelin Drug Profile | 51 | 1 |
| Gene Therapy to Activate Interleukin 10 for Atherosclerosis Drug Profile | 52 | 1 |
| Gene Therapy to Activate Interleukin-10 for ALS Drug Profile | 53 | 1 |
| LEO-32731 Drug Profile | 54 | 1 |
| MK-1966 Drug Profile | 55 | 1 |
| PD-2244 Drug Profile | 56 | 1 |
| Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease Drug Profile | 57 | 1 |
| Synthetic Peptides to Inhibit IL-10 and IFN Gamma for Cancer, Viral Infections and Inflammatory Diseases Drug Profile | 58 | 1 |
| XT-101 Drug Profile | 59 | 1 |
| XT-150 Drug Profile | 60 | 1 |
| Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Dormant Projects | 61 | 3 |
| Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Discontinued Products | 64 | 1 |
| Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Featured News &Press Releases | 65 | 11 |
| Sep 26, 2016: ARMO BioSciences Announces Data Presentations at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference | 65 | 1 |
| Aug 15, 2016: ARMO BioSciences Announces Publication of AM0010 Clinical Data in Advanced Solid Tumor Patients in Journal of Clinical Oncology | 66 | 1 |
| Jun 06, 2016: ARMO BioSciences AM0010 Demonstrates Promising Clinical Data as an Immuno-oncology Monotherapy and in Combination with an Anti-PD-1 Checkpoint Inhibitor in Advanced Solid Tumors, Including Immune-Resistant Cancers | 67 | 1 |
| Apr 20, 2016: ARMO BioSciences Announces AM0010 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting in June 2016 | 68 | 1 |
| Mar 31, 2016: Xalud Therapeutics Discovers Potential Solution for Opioid Abuse Crisis | 69 | 1 |
| Mar 16, 2016: ARMO BioSciences to Present New Clinical Trial Results for AM0010 at Upcoming Medical Conferences | 70 | 1 |
| Jan 08, 2016: ARMO BioSciences to Present at the 34th Annual J.P. Morgan HealthCare Conference | 70 | 1 |
| Oct 30, 2015: ARMO BioSciences Presents Positive Phase 1 Trial Results of AM0010 at Upcoming Medical Conferences | 71 | 1 |
| Oct 06, 2015: Biotest reaches the next milestone in the clinical development of its monoclonal antibody BT-063 by starting the clinical phase IIa trial in the indication systemic lupus erythematosus | 71 | 1 |
| Jun 01, 2015: ARMO BioSciences Announces Efficacy and Safety Data for Immuno-Oncology Program with Novel Mechanism of Action | 72 | 1 |
| May 13, 2015: ARMO BioSciences Announces Presentation on Promising Immuno-Oncology Program at 2015 ASCO Annual Meeting | 73 | 1 |
| Jun 23, 2014: Cytovance Biologics selected for GMP manufacture of AM0010 for ARMO BioSciences | 73 | 1 |
| Nov 25, 2013: ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy | 73 | 1 |
| Apr 11, 2012: University Of Leuven And ActoGeniX Announce Study Results Of ActoBiotic In Treatment Of Type 1 Diabetes | 74 | 1 |
| Sep 30, 2009: Biotest AG Announces Initiation of Clinical development of BT-063 | 75 | 1 |
| Appendix | 76 | 2 |
| Methodology | 76 | 1 |
| Coverage | 76 | 1 |
| Secondary Research | 76 | 1 |
| Primary Research | 76 | 1 |
| Expert Panel Validation | 76 | 1 |
| Contact Us | 76 | 1 |
| Disclaimer | 77 | 1 |
